163 related articles for article (PubMed ID: 15809716)
1. Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents.
Tassone P; Blotta S; Palmieri C; Masciari S; Quaresima B; Montagna M; D'Andrea E; Eramo OP; Migale L; Costanzo F; Tagliaferri P; Venuta S
Int J Oncol; 2005 May; 26(5):1257-63. PubMed ID: 15809716
[TBL] [Abstract][Full Text] [Related]
2. Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel.
Wang Z; Goulet R; Stanton KJ; Sadaria M; Nakshatri H
Anticancer Res; 2005; 25(3c):2367-79. PubMed ID: 16080463
[TBL] [Abstract][Full Text] [Related]
3. Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers.
Masuda A; Maeno K; Nakagawa T; Saito H; Takahashi T
Am J Pathol; 2003 Sep; 163(3):1109-16. PubMed ID: 12937152
[TBL] [Abstract][Full Text] [Related]
4. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells.
Tassone P; Tagliaferri P; Perricelli A; Blotta S; Quaresima B; Martelli ML; Goel A; Barbieri V; Costanzo F; Boland CR; Venuta S
Br J Cancer; 2003 Apr; 88(8):1285-91. PubMed ID: 12698198
[TBL] [Abstract][Full Text] [Related]
5. Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers.
Ooe A; Kato K; Noguchi S
Breast Cancer Res Treat; 2007 Mar; 101(3):305-15. PubMed ID: 16821082
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
[TBL] [Abstract][Full Text] [Related]
7. Molecular profiles of BRCA1-mutated and matched sporadic breast tumours: relation with clinico-pathological features.
Berns EM; van Staveren IL; Verhoog L; van de Ouweland AM; Meijer-van Gelder M; Meijers-Heijboer H; Portengen H; Foekens JA; Dorssers LC; Klijn JG
Br J Cancer; 2001 Aug; 85(4):538-45. PubMed ID: 11506493
[TBL] [Abstract][Full Text] [Related]
8. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers.
Byrski T; Gronwald J; Huzarski T; Grzybowska E; Budryk M; Stawicka M; Mierzwa T; Szwiec M; Wiśniowski R; Siolek M; Narod SA; Lubinski J;
Breast Cancer Res Treat; 2008 Mar; 108(2):289-96. PubMed ID: 17492376
[TBL] [Abstract][Full Text] [Related]
9. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
[TBL] [Abstract][Full Text] [Related]
10. N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells.
Simeone AM; Deng CX; Kelloff GJ; Steele VE; Johnson MM; Tari AM
Carcinogenesis; 2005 May; 26(5):1000-7. PubMed ID: 15695235
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer risk and the DNA double-strand break end-joining capacity of nonhomologous end-joining genes are affected by BRCA1.
Bau DT; Fu YP; Chen ST; Cheng TC; Yu JC; Wu PE; Shen CY
Cancer Res; 2004 Jul; 64(14):5013-9. PubMed ID: 15256476
[TBL] [Abstract][Full Text] [Related]
12. Subcellular localization of the BRCA1 gene product in mitotic cells.
Lotti LV; Ottini L; D'Amico C; Gradini R; Cama A; Belleudi F; Frati L; Torrisi MR; Mariani-Costantini R
Genes Chromosomes Cancer; 2002 Nov; 35(3):193-203. PubMed ID: 12353262
[TBL] [Abstract][Full Text] [Related]
13. Mutant BRCA1 genes antagonize phenotype of wild-type BRCA1.
Fan S; Yuan R; Ma YX; Meng Q; Goldberg ID; Rosen EM
Oncogene; 2001 Dec; 20(57):8215-35. PubMed ID: 11781837
[TBL] [Abstract][Full Text] [Related]
14. BRCA1 modulates malignant cell behavior, the expression of survivin and chemosensitivity in human breast cancer cells.
Promkan M; Liu G; Patmasiriwat P; Chakrabarty S
Int J Cancer; 2009 Dec; 125(12):2820-8. PubMed ID: 19551867
[TBL] [Abstract][Full Text] [Related]
15. Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: Relationship to lipid peroxidation and HER-2/neu expression.
Menendez JA; Ropero S; Lupu R; Colomer R
Oncol Rep; 2004 Jun; 11(6):1241-52. PubMed ID: 15138562
[TBL] [Abstract][Full Text] [Related]
16. The retinoblastoma gene undergoes rearrangements in BRCA1-deficient basal-like breast cancer.
Jönsson G; Staaf J; Vallon-Christersson J; Ringnér M; Gruvberger-Saal SK; Saal LH; Holm K; Hegardt C; Arason A; Fagerholm R; Persson C; Grabau D; Johnsson E; Lövgren K; Magnusson L; Heikkilä P; Agnarsson BA; Johannsson OT; Malmström P; Fernö M; Olsson H; Loman N; Nevanlinna H; Barkardottir RB; Borg Å
Cancer Res; 2012 Aug; 72(16):4028-36. PubMed ID: 22706203
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma.
Busacca S; Sheaff M; Arthur K; Gray SG; O'Byrne KJ; Richard DJ; Soltermann A; Opitz I; Pass H; Harkin DP; Quinn JE; Fennell DA
J Pathol; 2012 Jun; 227(2):200-8. PubMed ID: 22190288
[TBL] [Abstract][Full Text] [Related]
18. The predictive value of epidermal growth factor receptor expression for sensitivity to vinorelbine in breast cancer.
Ning YL; Qi CJ; Lu XZ; Zhu YL; Qian KQ; Zhao JZ
Basic Clin Pharmacol Toxicol; 2011 Dec; 109(6):499-505. PubMed ID: 21740526
[TBL] [Abstract][Full Text] [Related]
19. [Properties of antitumor activity of vinorelbine tartrate, a new vinca alkaloid antitumor agent].
Kanazawa J; Morimoto M; Ohmori K
Nihon Yakurigaku Zasshi; 2000 Oct; 116(4):215-23. PubMed ID: 11084918
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway.
Lafarge S; Sylvain V; Ferrara M; Bignon YJ
Oncogene; 2001 Oct; 20(45):6597-606. PubMed ID: 11641785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
